Innovative Biomarkers in de Novo Parkinson's Disease

  • STATUS
    Recruiting
  • End date
    Apr 24, 2024
  • participants needed
    120
  • sponsor
    University Hospital, Grenoble
Updated on 26 March 2021
tremor
movement disorder
bradykinesia
muscle rigidity
resting tremor

Summary

This study aims at identifying potential new and innovative biomarkers in de novo Parkinson's disease patients. New finding will help phenotyping patients since the diagnosis of the disease and potentially also in the preclinical phase.

Description

The investigators will use 4 different approaches in parallel:

  1. detailed clinical evaluation using the current available validated clinical scales and the Dopamine transporter (DAT) SPECT imaging;
  2. anatomical and perfusional brain evaluation using functional MRI;
  3. cortical brain mapping and transcranial magnetic stimulation assessment using a robotized approach;
  4. emotional responses study using a novel paradigm. These 4 modalities will be assessed at baseline, 1 year and 2 years follow-up.

The investigators will integrate these 4 analysis using a mathematical paradigm in order to define specific phenotype of disease and disease progression.

Details
Condition Parkinson's disease, Healthy Controls Group - Age and Sex-matched, Healthy Controls Group - Age and Sex-matched, parkinson's, parkinson disease, Healthy Controls Group - Age and Sex-matched, Healthy Controls Group - Age and Sex-matched, Healthy Controls Group - Age and Sex-matched
Treatment Brain MRI, TMS-EEG, Behavioral and cognitive battery, Clinical evaluation and clinical scales
Clinical Study IdentifierNCT03940677
SponsorUniversity Hospital, Grenoble
Last Modified on26 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Parkinson's disease
Asymmetric bradykinesia and/or resting tremor and rigidity since less than 2.5 years
Hoehn & Yahr 2/5
Montreal cognitive assessment 26/30

Exclusion Criteria

Treatment for Parkinson's disease (except selegiline and rasagiline)
Severe visual/retinal pathology revealed during ophthalmological assessment
Hyper-sensibility to gadolinium
Renal failure
Specific MRI contraindication
Specific TMS contraindication
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note